B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments in ...
Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...
Glucocorticoids and B-cell targeting therapies are the cornerstones of IgG4 disease treatment, according to data presented at ...
Immunotherapy is the form of treatment that redirects the immune system toward a pathogen or disease. In many cases, immunotherapy is referred to treating cancer. As tumors progress, they secrete ...
MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...
A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...
French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). The company’s tetraspecific antibody controlled tumors and improved survival in mice and ...
Four symptoms may indicate a possible relapse of diffuse large B-cell lymphoma. Learn more about them and when to contact a doctor. A relapse of diffuse large B-cell lymphoma can cause a variety of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results